Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $769.00 at Morgan Stanley

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price upped by Morgan Stanley from $768.00 to $769.00 in a report issued on Monday morning,Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

REGN has been the topic of several other research reports. Cantor Fitzgerald boosted their price target on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a research note on Monday. Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Scotiabank boosted their price target on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research report on Monday, November 24th. Finally, Royal Bank Of Canada raised their price objective on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $799.74.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $755.02 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.22 and a current ratio of 4.77. The company has a 50-day moving average of $758.27 and a 200-day moving average of $652.73. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $821.11. The company has a market capitalization of $79.35 billion, a price-to-earnings ratio of 18.17, a PEG ratio of 1.92 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $12.07 earnings per share. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.47%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 7.02% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock valued at $7,004,838,000 after buying an additional 26,884 shares in the last quarter. State Street Corp grew its stake in Regeneron Pharmaceuticals by 0.9% in the second quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock valued at $2,536,801,000 after acquiring an additional 42,343 shares during the period. Dodge & Cox increased its holdings in shares of Regeneron Pharmaceuticals by 18.9% in the third quarter. Dodge & Cox now owns 4,550,845 shares of the biopharmaceutical company’s stock worth $2,558,804,000 after acquiring an additional 724,562 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Regeneron Pharmaceuticals by 6.0% during the third quarter. Franklin Resources Inc. now owns 2,453,143 shares of the biopharmaceutical company’s stock worth $1,379,329,000 after purchasing an additional 139,647 shares during the period. Finally, Capital World Investors lifted its holdings in shares of Regeneron Pharmaceuticals by 1.6% during the 3rd quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock valued at $1,123,609,000 after purchasing an additional 32,348 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: JPMorgan sharply raised its price target to $950 and moved to “overweight,” signaling a sizable upside thesis tied to Regeneron’s recent results and trajectory. Benzinga
• Positive Sentiment: Oppenheimer reaffirmed “outperform” and lifted its target to $865, showing dealer conviction that Q4 results justify higher analyst estimates. Benzinga
• Positive Sentiment: Cantor Fitzgerald and Wells Fargo raised targets (to $800), with Cantor keeping an “overweight” view — reinforcing industrywide upgrades following the quarter. Benzinga
• Positive Sentiment: Regeneron highlighted EYLEA HD Phase 3 presentations at Angiogenesis 2026 (final 64‑week QUASAR and full ELARA results), which support the drug’s clinical profile and could underpin retinal franchise growth. EYLEA HD Presentations
• Positive Sentiment: Investors are digesting the company’s upbeat Q4 report (EPS and revenue beats) and accompanying earnings call commentary that boosted near‑term visibility. Q4 Earnings Transcript
• Neutral Sentiment: Morgan Stanley nudged its target to $769 but kept an “equal weight” rating — a modest adjustment that suggests limited conviction for sizable near‑term upside. TickerReport
• Neutral Sentiment: Truist trimmed its target slightly (to $818) but maintained a “buy,” reflecting minor calibration rather than a change in long‑term view. TickerReport
• Neutral Sentiment: Market commentary and pieces on Regeneron’s pipeline vs. valuation highlight a valuation gap and focus investors on execution of key pipeline catalysts over the next 12–24 months. Yahoo Finance

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.